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Abstract 
External Price Referencing (EPR) is applied more and more frequently worldwide by payers to 
control pharmaceutical prices. Together with the parallel trade of pharmaceuticals, EPR may result in 
lower pharmaceutical prices in higher-income countries and higher prices in lower-income countries, 
which implies that pharmaceutical expenditure grows more rapidly in the latter than in the former 
group. Our objective was to assess this hypothesis.  We used hierarchical linear models on country-
level panel data to show that – after controlling for compounding factors such as GDP, proportion of 
old-age population or life expectancy – the annual growth rate of pharmaceutical expenditure was 
2.1 percentage points larger in the lower- than in the higher-income members of the European 
Union between 2000 and 2008. This difference in trends became non-significant (0.6 percentage 
points) after the onset of the global economic crisis. There was no significant difference between 
lower- and higher-income countries in the growth rate of non-pharmaceutical health expenditure in 
either period. Our results indirectly support the presence of price convergence of pharmaceuticals 
among European countries, and EPR and parallel trade may provide reasonable explanation to the 
observed trend difference of pharmaceutical expenditure in the two groups of countries between 
2000 and 2008. This higher growth rate of pharmaceutical expenditure put extra burden on public 
health care budgets in lower-income countries and resulted in disproportionately more cost-
containment measures compared to higher-income countries after 2008. It remains to be seen 
whether disappearance of the difference in trend growth rates due to special health policy 
interventions in countries with economic difficulties is temporary or permanent.    
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Introduction 
In the European Union lower-income member states tend to spend less on health care both in 
absolute terms and as a percentage of GDP than their higher-income counterparts. However, as the 
price of medicines is less different across European countries compared to the costs of non-
pharmaceutical health care services and the salary of health care professionals, lower-income 
countries spend more on pharmaceuticals as a proportion of total health care spending or as a 
proportion of GDP than higher-income ones (Kaló et al. 2012b, see also Table 1 later). The 
potentially differing trends of pharmaceutical expenditure according to income are much less 
studied, although it may be interesting from the policy perspective of external price referencing 
(EPR) and the parallel trade of pharmaceuticals.     
External Price Referencing (EPR), or international reference pricing, involves the selection of a basket 
of countries to compare pharmaceutical prices and create a reference price for the country in 
question (Espin et al. 2011). The purpose of EPR, among others, may be to negotiate or set prices 
within a country (Kanavos et al. 2010).  
It is applied more and more frequently both worldwide and in Europe, by payers who are aiming to 
control pharmaceutical prices (Carone et al. 2012), and it seems to be an effective tool to reduce 
pharmaceutical prices (Galizzi et al 2011; Leopold et al. 2012). Regular price revision, referencing 
lower income countries and mandate of lowest price in the basket of reference countries are 
potentially important drivers of price reduction over time (Kaló et al. 2015). Countries may also 
benefit from lower pharmaceutical prices if they delay the pricing decisions of new pharmaceuticals 
until many other European countries have already concluded on the price.  
In the European Union, parallel trade of pharmaceuticals – when some products are legally imported 
from another country without the authorization of the manufacturer (Bouvy and Vogler 2013) – has 
similar, although indirect effects. In the lack of EPR and parallel trade, manufacturers may have more 
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incentives to adjust their prices to local purchasing power (this strategy is often called differential 
pricing), resulting in the increase of available funds for and global return on investment of 
pharmaceutical innovation, whilst ensuring lower prices and as a consequence, better access to 
medicines in lower income countries (Danzon and Towse 2003; Kaló et al. 2013). However, in the 
presence of EPR and parallel trade, to minimize price erosion, pharmaceutical companies try to 
implement narrow international price corridor for their most important medicines (Ridley 2005). 
Manufacturers also apply specific launch sequence by introducing their new products in countries 
with traditionally high pharmaceutical prices, and reference these prices in other low-price countries 
(Creativ-Ceuticals 2014; Leopold et al. 2014). 
As a testable consequence at the aggregate (country-) level, both EPR and parallel trade may result 
in lower pharmaceutical prices in higher-income countries and higher prices in lower-income 
countries, unless each higher-income country removes those countries from their reference basket 
that do not have comparable GDP per capita (Bouvy and Vogler 2013). In theory, this implies two 
potential consequences in lower income countries: (1) access to new pharmaceuticals becomes 
more limited for patients (Ridley 2005); and (2) the pharmaceutical expenditure grows more rapidly 
compared to higher-income countries. As limited patient access may have negative impact on the 
popularity of policymakers, they tend to approve increase in pharmaceutical spending, especially 
before parliamentary elections (Inotai et al. 2014). This may further increase the rate of 
pharmaceutical expenditure in lower -income countries. In the above theoretical framework, 
Boehler (2013) simulated pharmaceutical price changes in Europe due to EPR, and concluded that 
EPR results in narrow price corridor for new pharmaceuticals; there is a race to the bottom by 
countries to obtain the European floor price; and the European price erosion of new 
pharmaceuticals in the early period is faster than in later years.  
Unfortunately the time-order relationship between EPR, parallel trade and increased pharmaceutical 
expenditure in lower-income countries is difficult  to establish at an aggregate level, as e.g. the 
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continuously strengthened application of EPR in Europe has to be considered in its continuum 
instead of a single intervention point. As current research methodologies and limited availability of 
data on net pharmaceutical prices across Europe prevented us from exploring the causal relationship 
between EPR, parallel trade and pharmaceutical expenditure, our research considered addressing 
their implications only indirectly. If pharmaceutical expenditure did not grow faster in lower 
compared to higher income countries, the implication of EPR and parallel trade on the European 
price corridor of new pharmaceuticals cannot be as important as presented in several papers (Ridley 
2005; Kaló et al. 2013; Creativ-Ceuticals 2014). On the other hand, the presence of a well-measured 
difference in growth rates of pharmaceutical expenditure yields indirect support to these 
phenomena.            
Therefore our objective in this study was to assess hypothesis (2) above, i.e. whether the growth 
rate of pharmaceutical expenditure is truly greater in lower-income than in higher-income European 
countries. We used hierarchical linear models to control for compounding factors such as GDP, 
proportion of old age population and life expectancy at birth. We investigated the periods before 
and after the onset of the global economic crisis separately. 
In addition, we estimated the income elasticity of pharmaceutical expenditure and compared it to 
the income elasticity of health care expenditure in general, obtained in this paper or given elsewhere 
in the literature. It is reasonable to analyze pharmaceutical expenditure separately from other 
health expenditures since there is a remarkable cross-country variation both in its value and in its 
ratio to total health care expenditure in Europe (Lambrelli and O’Donnell 2009; OECD 2011). Our 
paper also contributes to the scant literature of modelling pharmaceutical expenditure in a cross-
country panel data setting (e.g. Clemente et al. 2008).         
 
Materials and methods 
7 
 
Data 
The analysis was carried out on aggregate data of 21 European countries (Austria, Belgium, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, 
Netherlands, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, United Kingdom) between 
2000 and 2012. The data originated from the OECD (OECD 2014) and Eurostat (European 
Commission 2014) databases.  
We selected variables that may influence health care expenditure in general and pharmaceutical 
expenditure in particular. According to Ke et al. (2011), health care expenditure is affected by 
income, demand side (demographic and epidemiological) factors, technological progress and the 
characteristics of the health system. These variables are also determinants of pharmaceutical 
expenditure (Clemente et al. 2008; Lambrelli and O’Donnell 2009). In our study we measured 
income with GDP per capita, demographic factors with the proportion of the population above the 
age of 65 years, and we proxied technological progress with life expectancy at birth (c.f. Dreger and 
Reimers 2005). The main dependent variable was the logarithm of pharmaceutical expenditure per 
capita but to compare our results with other studies we also used the logarithm of non-
pharmaceutical health expenditure per capita as dependent variable in alternative equations.  
As for monetary variables, euro was chosen as a common measure; national currency values (for 
Czech Republic, Denmark, Hungary, Poland, Sweden and the United Kingdom) appearing in the 
databases above were converted to euro on the given annual exchange rate available from public 
sources (ECB 2014). We chose to measure expenditure items in a common currency instead of 
national currency or purchasing power adjusted currency because the prices of pharmaceuticals in 
different countries are compared in euro at the time of introduction.   
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The data sources did not cover all country-years, resulting in the presence of missing data. Missing 
data points within years (altogether 16 out of 273 country-year points) were omitted from the 
analysis.  
Methods 
Association between potential explanatory variables and pharmaceutical expenditure as the 
outcome was assessed by performing descriptive statistical analysis. A series of linear regression 
models were fitted on each of the country-level explanatory variables and the outcome for the year 
with the most recent and complete recordings. Goodness of fit was evaluated by calculating 
correlation coefficients and by visual inspection of each fitted univariate model. The variables 
included in the exploratory analyses were GDP per capita (in euro), proportion of population above 
the age of 65 years (in per cent) and life expectancy at birth (in years). 
To distinguish between higher- and lower-income countries within the European Union, a given 
country was considered higher-income if its GDP per capita exceeded mean GDP per capita in 2000 
of the entire group of countries. Similarly, if the given country’s GDP per capita did not exceed the 
mean GDP per capita in 2000, the country was taken into account in the lower-income group. This 
group consists of all new EU member states included in the analysis as well as Spain, Portugal and 
Greece (altogether 9 countries), while the higher-income group includes the other 12 countries. As 
part of the preliminary analysis, we also examined graphically how the growth of pharmaceutical 
expenditure between 2000 and 2012 differed in the higher- vs. lower-income group. 
The two groups are well separated by income. Italy, the poorest member of the higher-income 
group, had 35 per cent larger GDP per capita in 2000 than Spain, the richest member of the lower-
income group. Meanwhile, nine members of the higher-income group were within the 35 per cent 
range of Italy and three members of the lower-income group were within the same range of Spain. 
The two groups were stable between 2000 and 2012: although there was some reordering of 
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countries within the groups, it remained true in the whole period that each country in the lower-
income group had smaller GDP per capita than any country in the higher-income group. 
For a more detailed analysis, we used hierarchical linear models (also known as random effects or 
mixed models) to describe the trends of pharmaceutical (and also of non-pharmaceutical) health 
spending levels in the higher- and lower-income group of countries, whilst controlling for the effect 
of multiple control variables and allowing country-specific random intercepts and random slopes 
(see e.g. Gelman and Hill 2007). More precisely, our main specification was:  
(1)  =	 +  ∗ 
 + +  
(2)  =	 +  
(3)  =  ∗  +  ∗  ∗  +  ∗ 
 +  ∗ 
 ∗  +	, 
where  denotes country and 
 denotes year. t=0 stands for year 2008 and hence t lies in interval [-
8,+4] for years between 2000 and 2012. We chose 2008 as the baseline year because it separates 
the periods before and after the onset of the global economic crisis. The crisis started in 2007-2008 
but EU-wide GDP still increased by 0.5 per cent in 2008 and fell (by 4.4. per cent) only in 2009.  
In equation (1) the dependent variable () is the logarithm of pharmaceutical expenditure per 
capita or of non-pharmaceutical health expenditure per capita, which are modelled with the time 
trend and with the vector of explanatory variables (). The latter contains the logarithm of GDP 
per capita, the proportion of population above 65 years and life expectancy at birth. As given in 
equation (3), the time trend depends on whether the country is a higher- or lower-income country 
(denoted by , the dummy variable for being in the lower-income group), on whether the year is 
before or after the onset of the global economic crisis (denoted by the  and 
 dummies, 
respectively) and on the interaction of these two variables. Hence in equation (3) the parameters 
  and   measure the growth in the higher-income group pre- and post-crisis, respectively, 
while the main parameters of interest are  and , which show the difference in growth 
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rates between the lower- and higher-income group before and after the onset of the crisis, 
respectively. The effects of the control variables are measured by the parameter vector . The latter 
can be interpreted as an elasticity if both the dependent and the explanatory variable are given on 
the logarithmic scale.  
To model the hierarchical (i.e. panel) structure of the data, the first-level intercept  and time trend 
 are allowed to vary by country (i.e. we allow country-specific random intercepts denoted by  
and random slopes denoted by  in equations (2)-(3)). Furthermore, we have the idiosyncratic error 
term  in equation (1). The three error terms  , , " are jointly normally distributed with 
variances #$
%, #&
%  and #'
%, respectively. The country-specific error terms are potentially correlated 
(their correlation coefficient is denoted by () but they are assumed to be independent of .    
We also fitted other models. In one specification, to examine the potential sensitivity of the results 
to the classification of countries into two groups, we measured economic development on a 
continuous scale and allowed the time trend to depend explicitly on initial (year 2000) logarithmic 
GDP per capita. More precisely, we estimated equation (3’) instead of (3): 
(3’)  = , ∗  + ), ∗  ∗ * + , ∗ 
 + ), ∗ 
 ∗ * +	, 
where *  denotes year 2000 logarithmic GDP per capita of country  relative to the average. That is, 
, and , show the average pre- and post-crisis trends, respectively, while ), and ), 
indicate the effect of a one per cent larger GDP per capita on the expenditure trends.  
In another specification we only allowed country-specific intercepts but not country-specific time 
trends, while in yet another model we allowed the idiosyncratic error term to follow an 
autoregressive process as in Baltagi and Wu (1999). Finally, we also estimated a simplified version of 
model (1)-(3) where the pre- and post-crisis periods are not treated separately, i.e.  =   and 
 = . In this specification  =  measures the growth of the dependent variable in 
the higher-income group and  =   shows the difference in growth rates between the 
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lower- and higher-income group, averaged for the whole period between 2000 and 2012 and after 
controlling for the explanatory variables. 
Data analysis was carried out by using the R statistical software, its lme4 package (Bates et al. 2014) 
and the Stata statistical software. 
 
Results and Discussion 
Table 1 shows descriptive statistics of the dependent and explanatory variables in the higher- and 
lower-income European countries between 2000 and 2012. Both pharmaceutical and non-
pharmaceutical health expenditure per capita were much lower in the lower-income group than in 
the higher-income group but there was a substantial variation (with the highest expenditure values 
in the lower-income group well exceeding the lowest expenditure values in the higher-income 
group). On average, the ratio of pharmaceutical to total health expenditure was 24 per cent in the 
lower-income and 14 per cent in the higher-income group, but again, the variations were large. 
Among the explanatory variables, the biggest difference between the two groups is observed in GDP 
per capita but life expectancy at birth was also markedly larger in higher-income countries than in 
lower-income ones.  
(Table 1 about here) 
Figure 1 shows the time trends of pharmaceutical expenditure in the higher- and lower-income 
countries, suggesting smaller initial expenditure but a larger growth rate of expenditure in the lower-
income than in the higher-income group between 2000 and 2008. The difference in trends 
disappeared after the onset of the economic crisis: both groups of countries experienced stagnating 
(or even slightly decreasing) pharmaceutical expenditure in nominal terms between 2009 and 2012.     
(Figure 1 about here) 
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Based on descriptive statistical methods, there is an associative relationship between 
pharmaceutical expenditure and the three explanatory variables examined in this paper (Figure 2). 
We obtained the following correlation coefficients with the logarithm of pharmaceutical expenditure 
in 2008: 0.757 (logarithm of GDP per capita), 0.157 (the proportion of population above the age of 
65) and 0.806 (life expectancy at birth). The bottom right panel of Figure 2 also shows that 
pharmaceutical expenditure is positively correlated with non-pharmaceutical health expenditure, 
although the relationship is far from deterministic (the correlation coefficient was 0.844 in 2008). 
Hence our strategy to examine the pharmaceutical expenditure separately from the rest of health 
expenditure – that is analyzed in more detail in the literature – is justified.     
(Figure 2 about here) 
Hierarchical linear models make it possible to examine the growth rates of pharmaceutical 
expenditure in the two groups of countries after controlling for the other explanatory variables. The 
first column of Table 2 displays the parameter estimates of model (1)-(3) using the logarithm of 
pharmaceutical expenditure as the dependent variable. After controlling for other compounding 
factors, the annual growth rate of pharmaceutical expenditure was higher by 2.1 percentage points 
(with 95% confidence interval [0.4, 3.7]) in the lower-income than in the higher-income group of 
countries between 2000 and 2008. However, this statistically significant and substantial trend 
difference disappeared after 2008. The results of model (1)-(3’) in the second column of Table 2 
show that an e.g. 10 per cent larger initial GDP per capita was associated with a 0.14 percentage 
point lower annual growth rate of pharmaceutical expenditure between 2000 and 2008 (with 95% 
confidence interval [-0.25, -0.02]). Again, the trend difference by GDP per capita disappeared after 
2008. Similar results (not shown here) were obtained when not the GDP per capita itself but the 
estimated potential GDP per capita (which intends to capture the pure economic performance of the 
countries in the absence of demand-side fluctuations) was used in the analysis.  
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The two other models used for robustness check and not reported in Table 2 (i.e. the random effects 
model without random slopes and the random effects model with autoregressive error terms) gave 
similar results: the trend difference was about 2.4 percentage points before the onset of the crisis 
and not significant after that.  
Meanwhile, even after controlling for other factors, the growth rate of pharmaceutical expenditure 
was much higher before 2008 than after it, so the flattened expenditure curves in Figure 1 cannot be 
fully explained by the changes in GDP per capita during the crisis. The GDP-adjusted trend growth 
rate was around 3.6 per cent on average, 2.7 per cent in the higher-income and 4.7 per cent in the 
lower-income countries until 2008. After 2008 the average growth rate was not significantly 
different from zero (-0.8 per cent) at the 5 per cent level, and there was no significant trend 
difference between the higher and lower-income countries. 
We also fitted models without separating the two sub-periods (they are not reported in Table 2). In 
this case no statistically significant trend difference was observed between the pharmaceutical 
expenditure of the higher- and lower-income countries.  
(Table 2 about here) 
The country-specific intercepts of the hierarchical linear model (equation (2) in model (1)-(3)) give 
information about the relative level of pharmaceutical expenditure of countries in 2008 after 
controlling for GDP per capita, proportion of old-age population and life expectancy. According to 
Table 3, Greece was characterized by the largest intercept, i.e. the largest expenditure compared to 
countries with similar income and other explanatory variables (c.f. Lambrelli and O’Donnell 2011, 
who analyzed failed attempts to control pharmaceutical expenditure in Greece). Table 3 also 
displays the country-specific time trends before and after the onset of the economic crisis 
(calculated from equation (3)). After controlling for the other explanatory variables, the model 
estimates a remarkably high (i.e. higher than 5 per cent) pre-crisis trend growth rate of 
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pharmaceutical expenditure for Estonia, Greece, Hungary, Ireland and the Slovak Republic (Greece 
having the largest slope). The vast majority of these countries belong to the lower-income group. 
Country-specific trend growth rates were generally negative or close to zero after 2008, with two 
exceptions (Greece and Ireland, both having trend growth rates above 2 per cent even in this 
period). 
Figure 3 gives a picture about the country-specific hypothetical time trends and about the aggregate 
time trends in higher- versus lower-income countries of pharmaceutical expenditure by assuming 
that the explanatory variables (GDP per capita, proportion of population above the age of 65 and life 
expectancy at birth) were fixed at the given country’s average level. These lines differ from those in 
Figure 1 because the effect of the explanatory variables was controlled for.    
(Table 3 about here) 
(Figure 3 about here)             
For comparison, the third and fourth columns of Table 2 provide estimates from models, in which 
the dependent variable is the logarithm of non-pharmaceutical health expenditure. In this case there 
is no statistically significant difference between the time trends of the higher- and lower-income 
countries in either period (although there is some difference in 2000-2008 if income is measured 
with GDP per capita on a continuous scale). Hence the difference of time trends observed above 
between the two groups is a feature of pharmaceutical expenditure not shared by health 
expenditure in general.   
It is also interesting to compare the coefficients of the logarithm of GDP per capita (i.e. the income 
elasticities) in various models. Table 2 shows that a one per cent increase of GDP per capita 
increases non-pharmaceutical health expenditure by around 0.90 per cent. This is roughly in line 
with other estimates in the literature, which generally yield elasticities slightly lower than one (e.g. 
the elasticity of 0.87 in Baltagi and Moscone 2010). The income elasticity of pharmaceutical 
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expenditure is slightly less (around 0.6) but note that in this model the effect of GDP is partially 
captured by a change in trends. 
Theory predicts that external price referencing and parallel trade reduce prices of new 
pharmaceuticals in higher-income countries, and increase drug prices in lower-income ones, hence 
the growth rate of pharmaceutical expenditure will be higher in the latter compared to the former 
group. In this paper we fitted various hierarchical linear models on country-level panel data to show 
that – even after controlling for compounding factors – this trend difference of growth rates was 
significant in the European Union between 2000 and 2008 but disappeared after the onset of the 
global economic crisis. Throughout the analysis we measured expenditure items in a common 
currency (euro) because pharmaceuticals can be regarded as tradeable goods hence their prices can 
be compared in a common currency – at least at the time of their introduction in a new country. 
Therefore, for the purpose of the specific examination of pharmaceutical expenditure as opposed to 
health expenditure in general, the use of purchasing-power-parity-adjusted series (such as e.g. in 
Clemente et al. 2008) or series in national currency is not justified. 
Our results support the presence of narrowing price corridor and the price convergence of 
pharmaceuticals among European countries because alternative explanations such as volume 
growth differences or composition effects are unlikely to explain the two percentage point annual 
difference between the expenditure growths of the two groups in the 2000-2008 period. Although 
aggregate pharmaceutical consumption by volume is difficult to measure and reliable data sources 
are rare, sporadic evidence suggests that differences in volume growth cannot be such large. The 
worldwide Hoebert et al. (2011) study estimates an only two percentage point growth difference in 
the overall 2000-2008 period in the volume of non-hospital pharmaceutical consumption (which 
usually constitutes the larger volume in total consumption) between high-income and upper-middle 
income countries defined more broadly than our classification. Hence we expect a similarly small 
volume growth difference within the European Union in the given period. It is also possible but 
16 
 
unlikely that a composition effect pushed up aggregate expenditure substantially more in the lower-
income than in the higher-income European countries because empirical studies suggest an effect in 
the opposite direction, i.e. that new medicines tend to be introduced earlier in the higher-income 
than in the lower-income European countries (Danzon et al. 2005). Hence we can conclude that 
price convergence lies in most part behind the observed expenditure trend differences, for which 
EPR and parallel trade provide the most plausible explanations (see also Glynn 2009; Leopold et al. 
2012).   
Higher growth rate of pharmaceutical expenditure put extra burden on health care budgets in lower-
income countries, and resulted in disproportionately more pharmaceutical cost-containment 
measures compared to higher-income countries after the onset of the global economic crisis(Vogler 
et al. 2011).Examples include Greece, Portugal, Spain, Ireland, Hungary and the Baltic countries 
(Vandoros and Stargardt 2013; Garuoliene et al. 2011; Rüütel and Pudersell 2011; Behmane and 
Innus 2011; Kaló et al. 2012a; Leopold et al. 2014). As a consequence the difference in trend growth 
rates disappeared after 2008. It remains to be seen whether this change due to cost-containment 
measures in countries with economic difficulties is temporary or permanent. If the EPR hypothesis is 
correct then the trend difference may return as soon as European economies achieve their normal 
growth path again.  
Finally, it should be noted that there may be competing models  for the trend difference of 
pharmaceutical expenditure in the two groups of countries. For instance, Lago-Penas et al. (2013) 
separated the long- and short-term effects of GDP on total health expenditure by including the 
potential GDP and the output gap (i.e. the trend and the cycle components of the GDP) as separate 
explanatory variables. However, pharmaceutical prices and pharmaceutical consumption should 
depend much less on the cyclical stance of the economy than other components of health 
expenditure such as the wage of health care employees, so a separate treatment of the potential 
GDP and output gap (which might partially explain the differing trends in the two groups) is much 
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less justified for pharmaceutical expenditure than for total health expenditure. Moreover, we did 
not observe different trend growth rates of non-pharmaceutical health expenditure in the two 
groups of countries even between 2000 and 2008, which suggests a pharmaceutical-specific 
explanation for the trend difference – and this again points towards the EPR and parallel trend 
hypothesis. 
 
Conclusion 
Our study is among the first analyses to prove the higher growth rate of pharmaceutical expenditure 
in lower-income countries, a potential consequence of narrowing European price corridor of 
pharmaceuticals. As causal relationship between EPR, parallel trade and higher growth rate of 
pharmaceutical expenditure in lower- vs. higher-income countries could not be established, and we 
could not control country specific pharmaceutical expenditure for changes in volume or prescription 
patterns, generalizability of our conclusions is limited. In the future, the examination of product-
level data of pharmaceutical consumption from different countries with panel data methods – as 
was done e.g. in Timur et al. (2011) without focusing on EPR and by Leopold et al. (2012) with 
descriptive and regression methods – may yield further evidence on the narrowing of the price 
corridor.    
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TABLES 
 
Table 1: Descriptive statistics of the variables in the higher- and lower-income European countries 
(2000-2012 combined) 
 Higher-income countries Lower-income countries 
 N Mean S.D. Min. Max. N Mean S.D. Min. Max. 
Pharmaceutical exp. 
per capita (euro) 
147 411 89 238 614 110 236 105 52 586 
Non-pharma health 
exp. per capita (euro) 
147 2535 643 1224 4344 110 772 421 176 1716 
Total health exp.  
per capita (euro)  
147 2946 662 1584 4646 110 1007 516 228 2113 
Pharmaceutical exp.  
/ GDP (per cent) 
147 1.28 0.39 0.45 1.93 110 1.84 0.40 1.11 2.84 
Total health exp. 
per GDP (per cent) 
147 8.82 1.68 4.61 11.77 110 7.51 1.41 4.73 10.23 
Pharma / total 
health exp. (per cent) 
147 14.4 3.5 6.5 23.3 110 24.8 4.9 16.7 40.2 
GDP per capita 
(1000 euro) 
156 34.2 11.5 21.0 80.8 117 12.6 5.0 4.4 23.6 
Population above 
65 years (per cent) 
156 16.1 2.3 10.7 21.0 117 15.5 2.1 11.4 19.8 
Life expectancy at birth 
(years) 
156 79.8 1.3 76.6 82.3 117 76.8 2.9 70.9 82.6 
Source: own calculations based on OECD, Eurostat and ECB data. 
Unweighted averages and standard deviations (S.D.) 
N = number of country-year observations
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Table 2: Estimation results from hierarchical linear models 
Dependent variable 
Log pharmaceutical  
expenditure  
per capita 
Log non-pharmaceutical  
health expenditure  
per capita 
  (1)-(3) (1)-(3’) (1)-(3) (1)-(3’) 
Trend equations (2000-2008) 
Trend (2000-2008) 
  0.0266***  0.0162***  
(0.0062)  (0.0055)  
Trend (2000-2008) *  
lower-income 
 0.0207**  0.0105  
(0.0084)  (0.0068)  
Average trend (2000-2008) 
,  0.0360***  0.0214*** 
  (0.0062)  (0.0052) 
Trend (2000-2008) * 
Log GDP per capita in 2000 
),  -0.0136**  -0.0110** 
  (0.0059)  (0.0048) 
Trend equations (2008-2012) 
Trend (2008-2012) 
  -0.0120*  0.0157**  
(0.0072)  (0.0063)  
Trend (2008-2012) *  
lower-income 
  0.0061  -0.0096  
(0.0096)  (0.0082)  
Average trend (2008-2012) 
,  -0.0078  0.0125** 
  (0.0064)  (0.0055) 
Trend (2008-2012) * 
Log GDP per capita in 2000 
),  -0.0093  0.0026 
  (0.0065)  (0.0054) 
Control parameters 
Log GDP per capita (euro) 
+,- 0.588*** 0.605*** 0.896*** 0.893*** 
(0.061) (0.062) (0.055) (0.055) 
Proportion of population  
above 65 years (per cent) 
+./	01 -0.0273** -0.0286** -0.0128 -0.0167 
(0.0129) (0.0129) (0.0112) (0.0115) 
Life expectancy at birth  
(years) 
+.2	34 0.0071 0.0024 0.0245** 0.0244** 
(0.0136) (0.0137) (0.0123) (0.0123) 
Constant 
 -0.164 0.0526 -3.361*** -3.261*** 
(1.116) (1.144) (1.008) (1.013) 
Hyperparameters 
Standard deviation of  #$ 
0.283*** 0.288*** 0.240*** 0.243*** 
(0.048) (0.049) (0.054) (0.051) 
Standard deviation of  #& 
0.017*** 0.016*** 0.013*** 0.013*** 
(0.003) (0.003) (0.002) (0.002) 
Standard deviation of  #' 
0.048*** 0.048*** 0.044*** 0.044*** 
(0.002) (0.002) (0.002) (0.002) 
Correlation of 5 and  ( 
0.327 0.344 -0.138 0.116 
(0.213) (0.204) (0.299) (0.297) 
Number of observations  257 
Number of countries  21 
Source: own calculations based on OECD, Eurostat and ECB data 
Standard errors are reported in parentheses. 
*** p<0.01, ** p<0.05, * p<0.1 
All models were estimated on the country panel between years 2000 and 2012. 
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Table 3: Estimated country-specific intercepts and time trends of pharmaceutical expenditure after 
controlling for compounding variables 
 
Country Intercept 
Annual time trend 
2000-2008 
Annual time trend 
2008-2012 
  
 
for 
 ≤ 2008 
 
for 
 > 2008 
Higher-income countries 
Austria 0.054 0.030 -0.009 
Belgium 0.376 0.026 -0.013 
Denmark -0.378 0.020 -0.019 
Finland -0.009 0.030 -0.009 
France 0.313 0.025 -0.014 
Germany 0.289 0.040 0.001 
Ireland 0.016 0.065 0.027 
Italy 0.245 0.009 -0.029 
Luxemburg -0.639 0.005 -0.034 
Netherlands -0.168 0.037 -0.002 
Sweden 0.011 0.019 -0.020 
United Kingdom -0.262 0.011 -0.028 
Average of higher income countries -0.013 0.026 -0.012 
Lower-income countries 
Czech Republic -0.189 0.045 -0.008 
Estonia -0.384 0.063 0.009 
Greece 0.461 0.081 0.028 
Hungary 0.210 0.057 0.003 
Poland -0.363 0.028 -0.026 
Portugal 0.226 0.030 -0.024 
Slovak Republic 0.050 0.056 0.003 
Slovenia 0.023 0.039 -0.014 
Spain 0.118 0.031 -0.023 
Average of lower income countries 0.017 0.048 -0.006 
Source: own calculations based on OECD, Eurostat and ECB data 
Results from the hierarchical linear model (equations (2) and (3)) on pharmaceutical expenditure per 
capita (first column in Table 2) 
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FIGURES 
 
Figure 1: Pharmaceutical expenditure per capita in the higher- (solid line) and lower-income (dashed 
line) group of countries, 2000-2012  
 
Source: own calculations based on OECD, Eurostat and ECB data 
Solid lines indicate higher-income, dashed lines lower-income countries.  
Lower panel shows data normalized to 2008=100%. Upper panel uses per capita values on the 
logarithmic scale. 
Graphs on the right show group-wise means (of higher- vs. lower-income countries). Group-wise 
means were calculated after imputation of missing values from the hierarchical linear model 
(originally 16 values were missing out of the 273 country-year data points).  
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Figure 2: Relationship of pharmaceutical expenditure per capita and other variables in 2008 
 
Source: own calculations based on OECD, Eurostat and ECB data 
Logarithmic scales are used for the expenditure variables and GDP. Univariate regression lines are 
displayed.   
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Figure 3: Estimated country-specific and average time trends of pharmaceutical expenditure when 
explanatory variables are fixed at their country-specific averages (solid lines: higher-income, dashed 
lines: lower-income countries) 
 
Source: own calculations based on OECD, Eurostat and ECB data 
Results from the hierarchical linear model on pharmaceutical expenditure per capita (first column in 
Table 2) when the explanatory variables are fixed at each country’s average level. 
Logarithmic scale is used.  
Solid lines indicate higher-income, dashed lines lower-income countries. 
The graph on the right shows group-wise means (of higher- vs. lower-income countries). 
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